ArticleClinical cancer research : an official journal of the American Association for Cancer Research2015

Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.

Jennifer E Amengual et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.